Paclitaxel displays clinical activity against a wide variety of solid tumors. However, resistance to paclitaxel significantly attenuates the response to chemotherapy. The ABC transporter subfamily C member 10 (ABCC10), also known as multi-drug resistance protein 7 (MRP7) efflux transporter, is a major mediator of paclitaxel resistance. In this study, we show that masitinib, a small molecule stem-cell growth factor receptor (c-Kit) tyrosine kinase inhibitor, at non-toxic concentrations, significantly attenuates paclitaxel resistance in HEK293 cells transfected with ABCC10. Our in vitro studies indicated that masitinib (2.5 μM) enhanced the intracellular accumulation and decreased the efflux of paclitaxel by inhibiting the ABCC10 transport activity without altering the expression level of ABCC10 protein. Furthermore, masitinib, in combination with paclitaxel, significantly inhibited the growth of ABCC10-expressing tumors in nude athymic mice in vivo. Masitinib administration also resulted in a significant increase in the levels of paclitaxel in the plasma, tumors and lungs compared to paclitaxel alone. In conclusion, the combination of paclitaxel and masitinib could serve as a novel and useful therapeutic strategy to reverse paclitaxel resistance mediated by ABCC10.
Introduction
Paclitaxel alone or in combination with other anti-neoplastic agents has been the first-line drug for the treatment of non-small cell lung cancer (1) . Paclitaxel is also used to treat a variety of other metastatic or advanced cancer, including metastatic ovarian, breast, head and neck cancer and advanced Kaposi's sarcoma (2) . The novel mechanism of action of paclitaxel provided the hope that it would demonstrate anti-neoplastic efficacy in multidrug resistant tumor cells (3) .
Unfortunately, as with other chemotherapeutic drugs, resistance is commonly seen with paclitaxel treatment. One emerging and recently identified cause for paclitaxel resistance is its active efflux from the cells due to the expression of the ATP-binding cassette subfamily C member 10 (ABCC10), also known as multidrug resistant protein 7 (MRP7), located on the basolateral cell surface (4-7). The human ABCC10 transporter is a 171-kDa protein containing three membrane spanning domains (MSD1, MSD2 and MSD3) and two nucleotide binding domains (NBD1 and NBD2), and belongs to the class of long ABCCs, such as ABCC1, ABCC2, ABCC3 and ABCC6. Apart from paclitaxel, ABCC10 is reported to mediate the cellular efflux of several other anti-neoplastic drugs, including docetaxel, vincristine, vinblastine, vinorelbine, cytarabine, gemcitabine, 2',3'-dideoxycytidine, 9-(2-phosphonyl methoxyethyl)adenine (PMEA), epothilone B and endogenous substances like estradiol-17β-D-glucuronide (E 2 17βG) and leukotriene C4 (5, 8, 9) .
Masitinib, a novel phenylaminothiazole-type derivative (Fig. 1A) is an inhibitor of the class III receptor tyrosine kinase stem-cell growth factor receptor (c-Kit), platelet-derived growth factor receptor α and β and the non-receptor tyrosine kinase Lyn (10, 11) . Masitinib is not active against kinases whose inhibition has been associated with significant toxic effects, such as breakpoint cluster region-ABL, vascular endothelial growth factor and endothelial growth factor (10, 12) . In a Phase II trial, masitinib has been reported to significantly increase the overall survival rate and progression-free survival in patients with locally advanced or metastatic gastrointestinal stromal tumor (13) (14) (15) (16) .
We have previously established that mechanistically unrelated compounds, such as cepharanthine (17) , nilotinib (18) , erlotinib (19) , tariquidar (20) and tandutinib (21) , can sensitize ABCC10-transfected HEK293/ABCC10 cells to paclitaxel. However, these compounds also inhibited ABCB1-mediated paclitaxel resistance, rendering them non-specific and toxic (22) (23) (24) .
Here we discover that masitinib, an inhibitor of receptor tyrosine kinases (10), at non-toxic concentrations, show previously unknown activity in antagonizing the efflux function of ABCC10 in vitro, thereby increasing the intracellular concentration of paclitaxel. We further demonstrate that masitinib enhanced paclitaxel-mediated inhibition of the growth of ABCC10-expressing tumor in a tumor xenograft mouse model in vivo and report the pharmacokinetics of paclitaxel in combination with masitinib. FBS and 1% of 100 times diluted 10,000 IU/ml penicillin-10,000 μg/ml streptomycin (25) . All in vitro experiments were conducted at 60% to 80% cell confluency. The human mast cell leukemia cell line HMC-1 was obtained from Dr. Andrea Cerutti (Icahn School of Medicine at Mount Sinai, NY) in 2012 and cultured in Iscove's DMEM, supplemented with 10% heat-inactivated FBS and 1% of 100 times diluted 10,000 IU/ml penicillin-10,000 μg/ml streptomycin (26, 27) .
Materials and Methods
Cells used in the in vivo experiments were trypsinized and centrifuged at 2000 rpm for 2 min at 25°C, washed twice with PBS, and reconstituted in DMEM at a concentration of 1×10 
Cell viability assay
A modified MTT assay was performed to detect the sensitivity of the cells to the anticancer drugs in vitro (28) . The cell numbers seeded into 96-well plates were 5,000/well for HEK293/pcDNA3.1 and HEK293/ABCC10. Every MTT assay was run in triplicate and drugs tested included paclitaxel (0.001 to 1 μM), docetaxel (0.001 to 1 μM), vinblastine (0.001 to 1 μM), vincristine (0.001 to 1 μM), cisplatin (0.1 to 100 μM), masitinib (0.625 μM, 1.25 μM and 2.5 μM), cepharanthine (2.5 μM), verapamil (10 μM), and PAK-104P (5 μM). After seeding cells in 180 μl medium in 96-well plates and incubating for 24 h at 37°C, 20 μl of the appropriate anticancer drug at various concentrations was added (20 μl of fixed concentration of test compound for reversal were added 1 h prior to adding anticancer drugs). Subsequently, the anticancer drugs, in DMEM supplemented with 10% FBS, were incubated at 37°C for 72 h.
After 72 h, 20 μl MTT (4 mg/ml) was added to each well. The plates were incubated at 37°C for another 4 h. The MTT with medium was removed from each well, and 100 μl of DMSO was 
Immunoblot analysis
To determine whether masitinib affects the expression of ABCC10, and is able to block c-Kit and p-c-Kit, cells were incubated with masitinib at 2.5 μM for different time periods (0, 24, 48, and 72 h). Then, approximately 6 x 10 5 cells were harvested and suspended in PBS, centrifuged at 2000 rpm for 2 min, followed by two washings with PBS. The lysis buffer (1X PBS, 0.1% SDS, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 100 mg/ml paminophenylmethylsulfonyl fluoride) and 1% aprotinin was added to the suspension followed by vortexing. The resuspended cells were kept on ice for 30 min, followed by centrifugation at 12,000 rpm for 20 min. The supernatant was separated and stored in -80°C for the experiment. 
Collection of plasma and tissues
In a separate group of experiments, mice bearing HEK293/ABCC10 tumors were divided into two groups: 1) vehicle pretreatment (given 1 h before paclitaxel) and (15 mg/kg); 2) masitinib pretreatment (12.5 mg/kg p.o.) and paclitaxel (n = 7). After treatment, animals were anesthetized and blood was obtained using supraorbital puncture and placed in heparinized tubes and plasma was harvested at 10, 30, 60, 120 or 240 min after paclitaxel administration in both groups. In addition, the tumors and lungs were removed, weighed, snap frozen in liquid nitrogen, and stored at -80°C until analysis (32) .
HPLC conditions
Quantification of paclitaxel was conducted using an isocratic Shimadzu LC-20AB liquid 
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CA). The injection volume was 20 µl, and the mobile phase used for the separation of paclitaxel in plasma and tissue homogenate samples consisted of acetonitrile and water (53:47, v/v) delivered at 1.0 ml/min flow rate. For paclitaxel detection, the Shimadzu UV SPD-20A (Shimadzu, OR) detector set at 227 nm was used. Data acquisition and analysis was achieved using LC Solution software version 1.22 SP1 (Shimadzu, OR). All samples were analyzed in duplicate. Under these chromatographic conditions, the total run time was 15 min with a retention time of 12 min for paclitaxel. Standard curves for paclitaxel in plasma and tissue homogenates were prepared in the ranges of 25-5000 ng/ml. The analytical method described in this work has been already established and validated previously (32, 33) .
Extraction of paclitaxel from plasma and tissue homogenate samples
A simple, one-step protein precipitation with acetonitrile was used for sample preparation.
Tumor and lung tissues were homogenized in saline (1:2 (v/v)). Paclitaxel was extracted from plasma and tissue homogenate samples by precipitation with acetonitrile in 1:1 and 1:2 ratios (v/v), respectively. Samples were vortexed for 1 min, followed by centrifugation for 10 min at 10,000 rpm. The supernatant was transferred to insert vials from which 20 µl was injected onto the HPLC column. Samples with concentrations higher than the calibration range limit were appropriately diluted to fit within the working calibration curve.
Statistical analyses
All experiments were repeated at least three times and the differences were determined using the two tailed student's t-test and statistical significance was determined at p < 0.05. 
Results
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2014; DOI: 10.1158/1535-7163.MCT-13-0743
Masitinib significantly enhances the sensitivity of HEK293/ABCC10 cells to paclitaxel
Before determining the effect of masitinib on paclitaxel resistance, we examined its effect on the growth of the cell lines used in our study using MTT assay. Based on the cytotoxicity assays, we chose to use masitinib (Fig. 1B) at concentrations of 0.625 µM, 1.25 µM and 2.5 µM because at these concentrations, at least 80-90% of the cells survived. Masitinib, at 0.625 µM, 1.25 µM and 2.5 µM, significantly decreased the resistance to paclitaxel and docetaxel in the HEK293/ABCC10 cell line as compared to the control HEK293/pcDNA3.1 cells (Table 1) . Cepharanthine (2.5 µM), which has been shown to inhibit ABCC10 function, significantly decreased the resistance of HEK293/ABCC10 to paclitaxel as compared to the parental HEK293/pcDNA3.1 (17) . The incubation of 2.5 μM of masitinib or cepharanthine did not significantly alter the IC 50 values of cisplatin, which is not a substrate for ABCC10 in HEK293/pcDNA3.1 and HEK293/ABCC10 cells (34) . Masitinib also significantly increased the response of HEK293/ABCC10 cells to vincristine and vinblastine, which are substrates of ABCC10 (Supplemental Table 1 ). In order to determine the effect of masitinib on the ABCB1 and ABCC1 transporters, we chose the HEK293/ABCB1 and HEK293/ABCC1 cells lines, which express the ABCB1 and ABCC1 transporters, respectively. We used paclitaxel and vincristine as substrates for ABCB1 and ABCC1, respectively. Masitinib did not significantly reverse ABCB1-and ABCC1-mediated resistance to paclitaxel or vincristine (Supplemental Table 2 (Fig. 2) .
Masitinib increases the cellular accumulation of [ 3 H]-paclitaxel in HEK293/ABCC10 cells
In order to determine the mechanism responsible for the reversal action of masitinib at the ABCC10 transporter, we examined the effect of masitinib on the intracellular accumulation of (Fig. 3A) . In addition, the results obtained with masitinib were comparable to those obtained using the known ABCC10 transport inhibitor cepharanthine.
Masitinib decreases the cellular efflux of [ 3 H]-paclitaxel in HEK293/ABCC10 cells
We further determined the amount of [ (Fig. 3B) .
Masitinib has no effect on the expression levels of ABCC10, c-Kit, and p-c-Kit
Immunoblot analysis of ABCC10 indicated a band with a molecular weight of about 171-kDa in the HEK293/ABCC10 cell lysates, suggesting the presence of ABCC10. In contrast, this band was not present in HEK293/pcDNA3.1, indicating the absence of the ABCC10 protein (Fig. 4A) .
In order to confirm that the paclitaxel resistance modulation by masitinib was not due to a decrease in the expression of the ABCC10 protein, we incubated the cells with masitinib (2. (Fig. 4B) . In a different set of experiment, we found that expression of c-Kit (145-kDa) and p-c-Kit (145-kDa) proteins were not detected in HEK293/pcDNA3.1 or HEK293/ABCC10 cell lysates where HMC-1 cell lysate was used as positive control (Supplemental Fig. 1 ). These findings suggested that the reversal of paclitaxel resistance by masitinib did not the result from the alteration in ABCC10, c-Kit or p-c-Kit protein expression.
Masitinib significantly potentiates the anticancer activity of paclitaxel in an ABCC10-expressing tumor-xenograft model
The i.p. dose of paclitaxel (15 mg/kg) used in this study was determined after a series of pilot experiments which indicated that it produced significant resistance in HEK293/ABCC10 tumorxenograft model compared to the HEK293/pcDNA3.1 tumor-xenograft model (32) . Masitinib, alone (12.5 mg/kg p.o.) or in combination with paclitaxel, did not produce any visible toxicity or phenotypic changes in the male athymic NCR nude mice. The tumors expressing the ABCC10 transporter showed significant resistance to 15 mg/kg i.p. dose of paclitaxel (Fig. 5A, B and C) . This is in contrast to HEK293/pcDNA3.1 tumor, which were almost completely eliminated by 15 mg/kg of paclitaxel (Supplemental Fig. 2A and B) . No apparent weight loss was observed among the treatment groups compared to animals treated with vehicle (Fig. 5D) . Masitinib (12.5 mg/kg, p.o.), in combination with paclitaxel (15 mg/kg, i.p.), significantly decreased the sizes, weights and tumor volumes of the tumors expressing the ABCC10 transporter (HEK293/ABCC10) over a period of 18 days, compared to animals treated with vehicle, masitinib alone or paclitaxel alone (p < 0.01; Fig. 5A , B and C, respectively). These results suggest that masitinib significantly attenuates paclitaxel resistance in tumors expressing the ABCC10 transporter. 
Masitinib increases the plasma and tumor paclitaxel concentration in ABCC10-expressing tumor-xenograft model
In a separate study, we measured the plasma, tumor and lung concentrations of paclitaxel in animals pretreated with vehicle or masitinib (12.5 mg/kg, p.o.) prior to the administration of paclitaxel (15 mg/kg, i.v.) . The pharmacokinetic data showed that co-administration of masitinib and paclitaxel produced a transient increase in the plasma levels of paclitaxel after 10 min of administration, but not at subsequent time points (Fig. 6A) . The combination of masitinib and paclitaxel significantly increased the intratumoral concentration of paclitaxel (69.93 ± 14.15 ng/ml) as compared to paclitaxel administration alone (16.31 ± 6.45 ng/ml, p < 0.05) (Fig. 6B) after 240 min following adminstration. However, the coadministration of masitinib and paclitaxel also did not significantly increase the concentration of paclitaxel in the lungs as compared to paclitaxel administration alone (Fig. 6C ) after 240 min following administration.
These data suggest that masitinib-induced paclitaxel sensitivity in ABCC10-expressing tumors is due at least in part to its direct inhibition of the transporter activity of ABCC10, thereby increasing the intracellular accumulation of paclitaxel. 
Discussion
One of the major findings of this study was that masitinib significantly enhanced the sensitivity of HEK293/ABCC10 cells to paclitaxel and docetaxel, and to other substrates, such as vinblastine and vincristine. In addition, masitinib did not significantly potentiate the toxic effect of cisplatin, a drug that is not a substrate for the ABCC10 transporter, further supporting the specificity of masitinib. To our knowledge, this is the first study demonstrating that masitinib 
